Heartfailure is the pathophysiologic state in which the heart, via an abnormality of cardiac function (detectable or not), fails to pump blood at a rate commensurate with the requirements of the metabolizing tissues and/or pumps only from an abnormally elevated diastolic filling pressure.
In patients with CHF, the risk of cardiac sudden death from ventricular tachycardia (VT) or ventricular fibrillation is considerable, and the degree of risk is correlated with the degree of decompensation and the degree of LV dysfunction.
Cardiac cachexia is found in long-standing heartfailure, particularly of the RV, because of anorexia from hepatic and intestinal congestion and sometimes because of digitalis toxicity.
It is predominantly a venodilator, and to a lesser extent, an arterial vasodilator that reduces cardiac preload and alleviates pulmonary congestion.
Cardiac resynchronization therapy can be combined with an ICD as a single device if a patient meets criteria for both devices, as often is the case.
Cardiac transplantation is reserved for otherwise healthy patients with end-stage congestive heartfailure with severely impaired function despite optimal medical therapy.
infant was admitted secondary to cardiacfailure, with cardiomegaly and pulmonary...
Cardiac Resynchronization Therapy Improves Quality of Life, Exercise Capacity for Certain Chronic HeartFailure Patients; MIRACLE ICD Trial Results Released in This Week's JAMA.
Noninvasive cardiac devices are proving good for hearts and hospitals.
Heartfailure, also called congestive heartfailure, is a life-threatening condition in which the heart can no longer pump enough blood to the rest of the body.
The most common causes of heartfailure are hypertension (high blood pressure) and coronary artery disease (for example, you have had a heart attack).
Heartfailure is usually a chronic illness, and it may worsen with infection or other physical stressors.
Cisplatin and gemcitabine have not been clearly associated with cardiacfailure, though cisplatin has been occasionally associated with acute as well as late arterial occlusive events such as myocardial infarction and cerebrovascular thrombotic events.
This study did not show a negative impact of bortezomib on the incidence of congestive heartfailure, which was comparable in both arms at 2 percent [13].
Increased expression of genes coding for ubiquitin-proteasome pathway was demonstrated in a rat cardiac hypertrophy model [14].
Cardiac Resynchronization Therapy for Treatment of Chronic HeartFailureCardiac resynchronization therapy by means of biventricular pacing is a fairly new procedure that is showing promise.
Features: Cardiac Resynchronization Therapy for Treatment of Chronic HeartFailureCardiac resynchronization therapy by means of biventricular pacing is a fairly new procedure that is showing promise.
The majority of implantations are performed transvenously in the Cardiac Electrophysiology Laboratory by advancing the LV lead retrograde into one of the coronary venous tributaries.
Pathogenesis of sodium and water retention in high-output and low-output cardiacfailure, nephrotic syndrome, cirrhosis, and pregnancy (2)
The initiator of retention has been proposed to be either a fall in cardiac output (e.g., low-output cardiacfailure and vasoconstrictor hypovolemic nephrotic syndrome) or peripheral arterial vasodilatation (e.g., high-output cardiacfailure, cirrhosis, arteriovenous fistula, and pregnancy).
Otherwise, when kidneys are healthy, either a fall in cardiac output or peripheral arterial vasodilatation may diminish arterial vascular filling and thereby initiate a series of hemodynamic and hormonal events that result in renal sodium and water retention (Fig.
Thus diastolic failure results in an increase in LVEDP without a rise in LVEDV (the combination of pulmonary oedema with a normal heart size should alert one to the possibility of diastolic failure (image).
In predominant diastolic failure, with normal chamber volume, LV may already be operating on flat portion of pressure-volume curve and any reduction of central blood volume may simply reduce stroke volume without a significant change in LVEDP.
In systolic failure aim is to reverse cause of impaired contractility and to increase stroke volume.
Commonly, doctors fail to properly diagnose patients who have suffered a stroke or other cardiac problems because the symptoms of these ailments can vary greatly.
When the medical professional falls below the requisite standard of care established by other medical providers by acting negligently, he or she may be guilty of medical malpractice.
If you or a loved one has suffered due to a physician’s failure to diagnose, you may have been a victim of medical malpractice.
CardioConnection features 3D animation of cardiac related symptoms and procedures, personal testimonials from real patients, and heart healthy dietary tips.
This site has been designed to provide patient education material about Hypertension, Dyslipidemia, Coronary Artery Disease, HeartFailure and Cardiac Rehabilitation so you and your family can learn more about your condition, as well as actions you can take in managing your health.
A disease resulting in arterial blockages of the heart and is a leading risk factor for heart attacks.
- failure leads to a reduction in blood ejected with each beat and increase in blood remaining after systole
- in severe myocardial dysfunction, cardiac output can only be maintained by an increase in venous pressure and sinus tachydcardia, further depressing ventricular function and leading to accumulation of pulmonary interstitial and alveolar fluid -> dyspnoea; venous hypertension also causes hepatic enlargement, ascites and dependant oedema
- systolic failure is related to coronary artery vascular disease and ischaemic heart disease, particularly myocardial infarction
NEJM -- Herceptin and the Heart -- A Molecular Modifier of CardiacFailure
Herceptin and the Heart ; A Molecular Modifier of CardiacFailure
Kenneth R. Chien, M.D., Ph.D. Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.
The Journal of CardiacFailure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heartfailure -pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.
Click here to go the the Journal of CardiacFailure web site.
See the Journal of CardiacFailure web site for additional information on:
Official Journal of the HeartFailure Society of America and the Japanese HeartFailure Society
By selecting the subscription option you will automatically receive and be billed for the new edition of Journal of CardiacFailure each year upon publication.
Your subscription can be cancelled at any time by calling our Customer Service department.